Pregabalin has demonstrated efficacy in the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as adjunctive therapy for adult patients with ...

Developed in partnership with Adalvo, MISABRI PR is available in three dosage strengths (82.5mg, 165mg and 330mg), offering a flexible dose range to meet individual patient needs (Ref SmPC).

The increasing cases of peripheral neuropathic pain, rise in screening for diabetic neuropathic pain among diabetics, increase in the geriatric population, and launch of new approved drugs, among ...

One of UK's leading pain specialists is today raising the alarm as research reveals that 1 in 3 adults in Bristol being treated for depression are living with undiagnosed chronic pain, often ...

Allosteric GABA A-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

Spinal cord stimulation can reduce pain and restore nerve function among patients with diabetic peripheral neuropathy.

The first patient has been dosed in a phase 2b trial evaluating the first-in-class agent Halneuron for those with neuropathic pain following chemotherapy. The first patient has been dosed in the phase ...

A painkiller developed by Germany's Algiax Pharma has shown efficacy in the treatment of chronic neuropathic pain ... 25% of the AP-325 treated patients showed a pain reduction of at least ...

Urcosimod ophthalmic solution (0.05% and 0.1%) is currently being evaluated in a phase 2 trial in patients aged 18 years and older with neuropathic corneal pain. The Food and Drug Administration ...

“Neuropathic pain affects people differently, so the guideline supports the provision of high-quality patient-centered care that considers needs, values and preferences,” said Ferraro.

"Neuropathic pain affects people differently, so the guideline supports the provision of high-quality patient-centered care, that considers needs, values and preferences," Ferraro said.